RT Journal Article
T1 Outpatient Antipsychotic Use and Severe COVID-19: Avoiding the Impact of Age in a Real-World Data Study
A1 Pintos‐Rodríguez, Samuel
A1 Visos‐Varela, Irene
A1 Rodríguez Fernández, Almudena
A1 Zapata Cachafeiro, Maruxa
A1 Piñeiro‐Lamas, María
A1 Herdeiro, Maria Teresa Ferreira
A1 García-Álvarez, Rosa María
A1 Figueiras Guzmán, Adolfo
A1 Salgado Barreira, Ángel
K1 Antipsychotics
K1 COVID-19
K1 Hospitalization
K1 Real-world data
K1 Age
AB BackgroundThe association between use of antipsychotics and COVID-19 outcomes is inconsistent, which may be linked to use of these drugs in age-related diseases. Furthermore, there is little evidence regarding their effect in the nongeriatric population. We aim to assess the association between antipsychotic use and risk of disease progression and hospitalization due to COVID-19 among the general population, stratifying by age.MethodsWe conducted a population-based, multiple case-control study to assess risk of hospitalization, with cases being patients with a PCR(+) test who required hospitalization and controls being individuals without a PCR(+) test; and risk of progression to hospitalization, with cases being the same as those used in the hospitalization substudy and controls being nonhospitalized PCR(+) patients. We calculated adjusted odds-ratios (aOR) and 95% confidence intervals (CI), both overall and stratified by age.ResultsAntipsychotic treatment in patients younger than 65 years was not associated with a higher risk of hospitalization due to COVID-19 (aOR 0.94 [95%CI = 0.69–1.27]) and disease progression among PCR(+) patients (aOR 0.96 [95%CI = 0.70–1.33]). For patients aged 65 years or older, however, there was a significant, increased risk of hospitalization (aOR 1.58 [95% CI = 1.38–1.80]) and disease progression (aOR 1.31 [95% CI = 1.12–1.55]).ConclusionsThe results of our large-scale real-world data study suggest that antipsychotic use is not associated with a greater risk of hospitalization due to COVID-19 and progression to hospitalization among patients younger than 65 years. The effect found in the group aged 65 years or older might be associated with off-label use of antipsychotics
PB Oxford Academic
SN 1461-1457
YR 2024
FD 2024-04-11
LK http://hdl.handle.net/10347/34868
UL http://hdl.handle.net/10347/34868
LA eng
NO International Journal of Neuropsychopharmacology, 27, 4 (2024) pyae020
NO This work was supported by the Carlos III Institute of Health via the “COV20/00470” project (co-funded by the European Regional Development Fund, “A Way to Make Europe”). Funding for open access charge by Universidade de Santiago de Compostela/CISUG
DS Minerva
RD 24 abr 2026